glp-1 drugs moa GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes Discovery of GLP-1–Based Drugs for
Description
Nomenclature of targets and ligands Key protein targets and ligands in this article are hyperlinked to corresponding entries in the IUPHAR/BPS Guide to PHARMACOLOGY ( and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander, Christopoulos, et al., 2019
doi:10.1007/s11154-021-09699-1 45
In particular, tell your provider if you have or have a past history of: Thyroid cancer Type 1 or type 2 diabetes Gastrointestinal disease Pancreatitis Liver disease Kidney disease Diabetic retinopathy Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding
Assess Risk Factors for Delayed Gastric Emptying: Dose escalation phase
Perspectives in weight control in diabetesSGLT2 inhibitors and GLP-1-glucagon dual agonism
It is available as a weekly subcutaneous injection or daily oral drops
